Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Amortization of Deferred Charges (2020 - 2025)

Historic Amortization of Deferred Charges for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $800000.0.

  • Xeris Biopharma Holdings' Amortization of Deferred Charges changed 0.0% to $800000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 2018.48%. This contributed to the annual value of $3.0 million for FY2024, which is 3637.19% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Amortization of Deferred Charges stood at $800000.0, which was down 0.0% from $800000.0 recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Amortization of Deferred Charges registered a high of $844000.0 during Q1 2025, and its lowest value of $219000.0 during Q1 2022.
  • For the 5-year period, Xeris Biopharma Holdings' Amortization of Deferred Charges averaged around $542736.8, with its median value being $548000.0 (2023).
  • In the last 5 years, Xeris Biopharma Holdings' Amortization of Deferred Charges plummeted by 1274.9% in 2022 and then soared by 15022.83% in 2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Amortization of Deferred Charges (Quarter) stood at $273000.0 in 2021, then skyrocketed by 79.12% to $489000.0 in 2022, then grew by 3.27% to $505000.0 in 2023, then soared by 59.8% to $807000.0 in 2024, then dropped by 0.87% to $800000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $800000.0 for Q3 2025, versus $800000.0 for Q2 2025 and $844000.0 for Q1 2025.